Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine

The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.

Raccontata dabiopharmadive.com